Beamr video compression achieves up to 50% improvement for AVs
Investing.com - H.C. Wainwright has reiterated its Buy rating and $81.00 price target on Crinetics (NASDAQ:CRNX) following the ENDO 2025 conference. The target represents significant upside from the current price of $31.11, with analyst targets ranging from $36 to $97, according to InvestingPro data.
The research firm observed strong enthusiasm from expert endocrinologists toward Palsonify (paltusotine), noting that many medical professionals described the drug as a "game changer" in acromegaly treatment compared to current standard-of-care options.
H.C. Wainwright highlighted that unlike injectable treatments, paltusotine has demonstrated consistent biochemical and symptom control while reducing breakthrough symptoms in acromegaly patients.
The firm emphasized the drug’s once-daily dosing regimen as a key advantage, allowing patients to take it at bedtime without concerns about fasting and food effects that are challenges with twice-daily oral somatostatin receptor ligands (SRLs).
Endocrinologists consulted by the firm reportedly expect most of their acromegaly patients to switch to paltusotine, reinforcing H.C. Wainwright’s confidence in maintaining its Buy rating and $81 price target for Crinetics.
In other recent news, Crinetics Pharmaceuticals presented significant long-term data on its lead drug candidate, paltusotine, during the ENDO’25 conference. Jones Trading reiterated a Buy rating with a $71 price target, highlighting the sustained biochemical control observed in the PATHFNDR-1 and PATHFNDR-2 studies for acromegaly. JMP Securities also maintained a Market Outperform rating, assigning a 90% probability of paltusotine’s approval by its September 25 PDUFA date, viewing it as a major catalyst for the company. H.C. Wainwright continues to support Crinetics with a Buy rating, emphasizing the company’s drug discovery capabilities and expressing confidence in CRN12755 for Graves’ Disease. Meanwhile, Goldman Sachs initiated coverage with a Neutral rating, citing uncertainties around the launch of paltusotine and projecting less than $600 million in risk-adjusted peak sales. The firm also noted the potential of atumelnant in congenital adrenal hyperplasia (CAH) but expressed concerns over its Phase 3 study risks. Crinetics is advancing its pipeline with plans to begin pivotal trials for atumelnant in CAH and Cushing’s syndrome, while also focusing on its preclinical assets. These developments highlight Crinetics’ ongoing efforts in advancing its therapeutic pipeline across multiple indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.